Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 328 participants.

Also called NCT02203916

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 328 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02203916
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02203916. Randomized; quadruple masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2016-12-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
Condition
Hypertension
Intervention (Drug)
Azilsartan medoxomil
Intervention (Drug)
Azilsartan medoxomil placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02203916
Content hash
d3966b7f291094dcc54dd9c55e27d61101e8dff3d032f86c21c913ae7fd5ec0e